Loading company…
NextVivo develops immune organoid models for drug discovery and testing.
NextVivo develops three-dimensional immune organoid models that reproduce healthy and diseased human tissues for drug development. Its work focuses on oncology, infectious diseases and autoimmune disorders, serving pharmaceutical companies, biotech firms and academic institutions. The company is based in Palo Alto, US. In June 2022, it raised USD 7.90 mn in funding led by Khosla Ventures, with Alexandria Venture Investments and Wilson Sonsini Goodrich & Rosati among the investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in